Strasbourg, France, October 9, 2014 - Transgene SA (NYSE-Euronext: TNG) announced today the further strengthening of its management team following the recent arrival of Eric Quémeneur as Executive Vice President, Vice President Research & Development. The management committee of Transgene, chaired by Philippe Archinard, Chairman and Chief Executive Officer, is now composed of: Eric Quémeneur; Dr Nathalie Adda, Vice President, Chief Medical Officer; Christophe Ancel, Vice President Quality and Qualified Person; Jean-Philippe Del, Vice President Finance; Thibaut du Fayet, Vice President Alliance Management, Project Management and Marketing; Colin Freund, Vice President Business Development; Patrick Mahieux, Vice President Industrial and Pharmaceutical Operations; and Hemanshu Shah, Vice President Medical Affairs. Stéphane Boissel, Executive Vice President and Chief Financial Officer, announced that he is leaving the Company to pursue other opportunities.
Philippe Archinard, Chairman and Chief Executive Officer, said: "With this new management committee, Transgene now has a transatlantic management team of talented and experienced managers able to execute the next important phases of the Company's development. I wish to thank Stéphane for the positive contributions he has made to the organization and development of Transgene during the past four years and wish him well in his future endeavours."
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.70 (c)||0.00%||37 487|